JP2009084204A - Whey protein nutritional composition - Google Patents
Whey protein nutritional composition Download PDFInfo
- Publication number
- JP2009084204A JP2009084204A JP2007255645A JP2007255645A JP2009084204A JP 2009084204 A JP2009084204 A JP 2009084204A JP 2007255645 A JP2007255645 A JP 2007255645A JP 2007255645 A JP2007255645 A JP 2007255645A JP 2009084204 A JP2009084204 A JP 2009084204A
- Authority
- JP
- Japan
- Prior art keywords
- whey protein
- emulsifier
- nutritional composition
- glyceryl monostearate
- nutrition composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010046377 Whey Proteins Proteins 0.000 title claims abstract description 123
- 102000007544 Whey Proteins Human genes 0.000 title claims abstract description 122
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 121
- 235000021119 whey protein Nutrition 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims abstract description 115
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 57
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 230000001954 sterilising effect Effects 0.000 claims abstract description 29
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 27
- -1 organic acid monoglycerides Chemical class 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 12
- 239000000194 fatty acid Substances 0.000 claims abstract description 12
- 229930195729 fatty acid Natural products 0.000 claims abstract description 12
- UESKBWLOSBQYHI-UHFFFAOYSA-N 2,3-dihydroxypropyl octadecanoate;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO UESKBWLOSBQYHI-UHFFFAOYSA-N 0.000 claims abstract description 7
- JIKRKVMHCXOTQQ-UHFFFAOYSA-N diacetyl 2,3-dihydroxybutanedioate;2,3-dihydroxypropyl octadecanoate Chemical compound CC(=O)OC(=O)C(O)C(O)C(=O)OC(C)=O.CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO JIKRKVMHCXOTQQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 5
- 238000002844 melting Methods 0.000 claims abstract description 5
- 230000008018 melting Effects 0.000 claims abstract description 5
- WSHAIDIHLZNVFW-UHFFFAOYSA-N butanedioic acid;2,3-dihydroxypropyl octadecanoate Chemical compound OC(=O)CCC(O)=O.CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO WSHAIDIHLZNVFW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000035764 nutrition Effects 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 17
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 11
- 235000010755 mineral Nutrition 0.000 claims description 11
- 239000011707 mineral Substances 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 abstract description 10
- 238000000265 homogenisation Methods 0.000 abstract description 8
- 230000009469 supplementation Effects 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000011632 Caseins Human genes 0.000 description 11
- 108010076119 Caseins Proteins 0.000 description 11
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 11
- 235000021240 caseins Nutrition 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000005018 casein Substances 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- CPTAWIKLJZKYSK-UHFFFAOYSA-N 2-hydroxypropanoic acid;octadecanoic acid;propane-1,2,3-triol Chemical compound CC(O)C(O)=O.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CPTAWIKLJZKYSK-UHFFFAOYSA-N 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- XIQYDXFBXVKUGF-UHFFFAOYSA-N 1,2,5,6-tetrahydroxyhexan-3-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C(O)CO)CC(O)CO XIQYDXFBXVKUGF-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XYBGJCJJYSXIHI-UHFFFAOYSA-N 4-(2,3-dihydroxypropoxy)-4-oxobutanoic acid;octadecanoic acid Chemical compound OCC(O)COC(=O)CCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O XYBGJCJJYSXIHI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229940108925 copper gluconate Drugs 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000012245 magnesium oxide Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011670 zinc gluconate Substances 0.000 description 2
- 235000011478 zinc gluconate Nutrition 0.000 description 2
- 229960000306 zinc gluconate Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FDKAAIFOPLCYAM-UHFFFAOYSA-M C(C(O)C)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[Ca+] Chemical compound C(C(O)C)(=O)[O-].C(CCCCCCCCCCCCCCCCC)(=O)[Ca+] FDKAAIFOPLCYAM-UHFFFAOYSA-M 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920002245 Dextrose equivalent Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010065713 Gastric Fistula Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- WTAYIFXKJBMZLY-XZABIIKCSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O WTAYIFXKJBMZLY-XZABIIKCSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- VEJCUEBBRSCJRP-UHFFFAOYSA-L calcium;hydron;phosphonato phosphate Chemical compound [Ca+2].OP(O)(=O)OP([O-])([O-])=O VEJCUEBBRSCJRP-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- BWFPGXWASODCHM-UHFFFAOYSA-N copper monosulfide Chemical compound [Cu]=S BWFPGXWASODCHM-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- SELHWUUCTWVZOV-UHFFFAOYSA-N dodecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCC(O)=O SELHWUUCTWVZOV-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 201000009868 osmotic diarrhea Diseases 0.000 description 1
- 208000028719 osmotic diarrheal disease Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【課題】乳清たんぱくを配合しても特定の乳化剤を組み合わせて乳化を行うことにより、製造工程中の均質化処理や加熱殺菌処理に耐え、調製後も乳化安定性が確保され、内容成分が均質で風味が良好であり、栄養補給を必要とする高齢者や患者等への栄養補給の際に摂取できるようにした、乳清たんぱく栄養組成物を提供すること。
【解決手段】乳清たんぱくを含有する栄養組成物において、乳化剤として以下の(A)および(B)を含有し、(A)1重量部に対して乳化剤(B)を0.5〜3重量部使用し、加熱殺菌後に液状である乳清たんぱく栄養組成物。(A)コハク酸グリセリンモノステアレート、乳酸グリセリンモノステアレート、ジアセチル酒石酸グリセリンモノステアレート、からなる群から選ばれる1以上の有機酸モノグリセリド、(B)HLB値が12〜14、および、乳化剤を構成する脂肪酸の融点が60℃以下であるポリグリセリン脂肪酸エステル。
【選択図】なし[Problem] Even if whey protein is blended, emulsification is carried out in combination with a specific emulsifier, so that it can withstand homogenization and heat sterilization during the manufacturing process, and stability of emulsification is ensured even after preparation. To provide a whey protein nutritional composition that is homogeneous and has a good flavor and that can be taken during nutritional supplementation for the elderly and patients who need nutritional supplementation.
A nutritional composition containing whey protein contains the following (A) and (B) as emulsifiers, and (A) 0.5 to 3 weights of emulsifier (B) with respect to 1 part by weight. Whey protein nutritional composition that is partly used and is liquid after heat sterilization. (A) one or more organic acid monoglycerides selected from the group consisting of glyceryl monostearate succinate, glyceryl monostearate lactate, glyceryl monostearate diacetyl tartrate, (B) an HLB value of 12-14, and an emulsifier Polyglycerin fatty acid ester whose melting point of the fatty acid which comprises is 60 degrees C or less.
[Selection figure] None
Description
本発明は経管投与または経口摂取で栄養補給を必要とする高齢者や患者等に対して、効率的にたんぱく質、脂質、糖質、ビタミン、ミネラル等の補給ができる栄養組成物に関する。
更に詳しくは、栄養価の高い良質のたんぱく質として乳清たんぱくを使用し、特定の乳化剤の組み合わせで乳化することにより、加熱殺菌後も乳化安定性が良好となる、乳清たんぱく栄養組成物に関するものである。
The present invention relates to a nutritional composition capable of efficiently supplementing proteins, lipids, carbohydrates, vitamins, minerals and the like to elderly people and patients who need nutritional supplementation by tube administration or oral intake.
More specifically, the present invention relates to a whey protein nutrition composition that uses whey protein as a high-quality protein with high nutritional value and is emulsified with a combination of specific emulsifiers, so that the emulsion stability is improved even after heat sterilization. It is.
経腸栄養法は経静脈栄養法に比べて生理的で、小腸粘膜の機能を維持し、バクテリアルトランスロケーションを予防することが可能な方法で、合併症の予防、在院日数の短縮が可能になる等有用性が高い。経腸栄養法に用いられる栄養組成物は、たんぱく質、脂質、糖質、ビタミン、ミネラル等が配合されており、通常の食事等を摂取できない手術前後の患者、高齢者等に栄養補給を行い、その体力等の回復や治癒を促進させるものとして欠かせないものである。特に、高齢者の大半は、たんぱく質・エネルギー低栄養状態(Protein Energy Malnutrition:PEM)や、低たんぱく血症等にあるといわれているだけに、栄養組成物による各種栄養成分、特にたんぱく質の補給が重要となる。
現在経腸栄養法で使用される栄養組成物は、たんぱく質を使用したものが最も汎用されており、そのたんぱく質は、カゼインあるいはカゼインを多く含む乳たんぱくが使用されている。
一方で、乳清たんぱくは、カゼインと比べて、全構成アミノ酸に対する8種類の必須アミノ酸の比率が高く、分岐鎖アミノ酸や含硫アミノ酸を高濃度に含んでいる栄養価が高いたんぱく質である。その他にもラクトフェリンや抗体成分、種々の機能性ペプチド等ヒトに対して有益性をもたらす多くの成分を含有している。乳清たんぱくは消化吸収も優れており、胃内で分解されなくてもアミノ酸酸化やたんぱく質合成を促進する。等量のカゼイン、あるいは、乳清たんぱくを摂取後の血漿総アミノ酸濃度は、乳清たんぱくがカゼインと比較して高値を示すことが示されている。このため、病気また手術から回復しつつある回復期の患者、高齢者等の限られた食欲を有する患者に対して、乳清たんぱくは、カゼインよりも有効なたんぱく質となる。
Enteral nutrition is more physiological than parenteral nutrition, maintains the function of the mucous membrane of the small intestine, and prevents bacterial translocation, which can prevent complications and shorten hospital stays. The usefulness is high. The nutritional composition used for enteral nutrition is formulated with proteins, lipids, carbohydrates, vitamins, minerals, etc., providing nutrition to patients before and after surgery that cannot take a normal meal, etc. It is indispensable for promoting recovery and healing of the physical strength. In particular, most elderly people are said to have protein and energy malnutrition (Protein Energy Malnutrition: PEM) and hypoproteinemia. It becomes important.
The most widely used nutritional composition currently used in enteral nutrition is protein, and the protein is casein or milk protein containing a lot of casein.
On the other hand, whey protein has a higher ratio of eight essential amino acids to all constituent amino acids than casein, and is a highly nutritious protein containing branched chain amino acids and sulfur-containing amino acids at high concentrations. In addition, it contains many components that bring benefits to humans, such as lactoferrin, antibody components, and various functional peptides. Whey protein is excellent in digestion and absorption, and promotes amino acid oxidation and protein synthesis without being broken down in the stomach. It has been shown that the plasma total amino acid concentration after ingesting an equal amount of casein or whey protein is higher in whey protein than in casein. For this reason, whey protein is a more effective protein than casein for patients with limited appetite, such as patients in recovery phase who are recovering from disease or surgery, and elderly people.
しかし、乳清たんぱくをたんぱく質とした栄養組成物は、カゼインと比較して乳化性、乳化安定性に劣るため、カゼインを用いた場合と同様の方法で調製した場合、脂質が早期にクリーミングや分離を生じる。このため、乳清たんぱくをたんぱく質とした栄養組成物は、従来の栄養組成物のように室温での流通・保存に耐え得るものではなかった。これは、ランダムコイル構造のカゼインに比べて、球状構造の乳清たんぱくは、乳化性に劣る、すなわち油/水界面への吸着が弱かった。さらに、カゼインは、界面に吸着したカゼイン同士の反発力はイオン強度に関係しないため、ミネラルの影響を受けにくく安定であるが、乳清たんぱくでは、ミネラルを強化すると、ミネラルの影響を受け、油滴の凝集が起こりやすくなるといった問題があった。
さらに、このような栄養組成物は、苛酷な均質化処理や加熱殺菌処理を施すため、たんぱく質−脂質複合体の構造変化が引き起こされ、乳化安定性が損なわれてしまい、消費者に供するに十分な栄養組成物が調製されるには至っていない。
このため、栄養価の高い良質のたんぱく質として乳清たんぱくを使用し、たんぱく質、脂質、糖質、ビタミン、ミネラル等を十分量、バランス良く配合した栄養組成物を提供するには、加熱殺菌処理を施しても調製でき、かつ、室温での流通・保存に耐え得る乳化安定性の良い乳清たんぱく栄養組成物の調製が望まれていた。
However, the nutritional composition made from whey protein as a protein is inferior in emulsification and emulsion stability compared to casein, so when it is prepared in the same way as with casein, lipids are creamed and separated early. Produce. For this reason, the nutritional composition using whey protein as a protein cannot withstand distribution and storage at room temperature unlike conventional nutritional compositions. This is because the whey protein with a spherical structure was inferior in emulsifiability, that is, the adsorption to the oil / water interface was weaker than the casein with a random coil structure. Furthermore, casein is stable because it is not easily affected by minerals because the repulsive force between the caseins adsorbed on the interface is not related to ionic strength, but whey protein is affected by minerals when oil is strengthened. There was a problem that droplet aggregation was likely to occur.
Furthermore, since such a nutritional composition is subjected to severe homogenization treatment and heat sterilization treatment, the structural change of the protein-lipid complex is caused, and the emulsion stability is impaired, which is sufficient for use by consumers. No nutritional composition has been prepared.
Therefore, to provide a nutritional composition that uses whey protein as a high-quality protein with high nutritional value and contains a sufficient amount of protein, lipids, sugars, vitamins, minerals, etc. in a well-balanced manner, heat sterilization treatment is required. There has been a demand for the preparation of a whey protein nutritional composition that can be prepared by application and has good emulsification stability that can withstand distribution and storage at room temperature.
本発明は、上記の状況に鑑みてなされたもので、乳清たんぱくを配合しても特定の乳化剤を組み合わせて乳化を行うことにより、製造工程中の均質化処理や加熱殺菌処理に耐え、調製後も乳化安定性が確保され、内容成分が均質で風味が良好であり、栄養補給を必要とする高齢者や患者等への栄養補給の際に摂取できるようにした、乳清たんぱく栄養組成物を提供するものである。 The present invention has been made in view of the above situation, and even when whey protein is blended, by emulsifying in combination with a specific emulsifier, it can withstand homogenization treatment and heat sterilization treatment during the production process, and can be prepared. Whey protein nutritional composition that ensures stable emulsification, has a homogeneous content, has a good flavor, and can be ingested during nutritional supplementation for the elderly and patients who need nutritional supplementation. Is to provide.
我々は、上記課題を解決するために鋭意検討を重ねた結果、乳清たんぱく栄養組成物の乳化に適した乳化剤の選択とその組み合わせによって加熱殺菌処理後も乳化安定性の良い乳清たんぱく栄養組成物を得られることを見出した。
すなわち、本発明は、以下の(1)〜(5)に示したものである。
(1)乳清たんぱく、脂質、糖質、ビタミン、ミネラルを含有する栄養組成物において、乳化剤として以下の(A)および(B)を含有し、(A)1重量部に対して乳化剤(B)を0.5〜3重量部配合し、加熱殺菌後に液状である乳清たんぱく栄養組成物。
(A)コハク酸グリセリンモノステアレート、乳酸グリセリンモノステアレート、ジアセチル酒石酸グリセリンモノステアレート、からなる群から選ばれる1以上の有機酸モノグリセリド、
(B)HLB値が12〜14、および、乳化剤を構成する脂肪酸の融点が60℃以下であるポリグリセリン脂肪酸エステル。
(2)加熱殺菌後の製剤における脂肪球の平均粒径が0.4μm以下である上記(1)に記載の乳清たんぱく栄養組成物。
(3)(B)から選ばれる乳化剤がデカグリセリンモノミリステート、および/または、デカグリセリンモノオレエートである上記(1)または(2)に記載の乳清たんぱく栄養組成物。
(4)加熱殺菌方法がレトルト殺菌、UHT殺菌である上記(1)〜(3)のいずれかに記載の乳清たんぱく栄養組成物。
(5)加熱殺菌後の粘度が常温で30mPa・s以下である上記(1)〜(4)のいずれかに記載の乳清たんぱく栄養組成物。
As a result of intensive studies to solve the above-mentioned problems, we have selected whey protein nutrition composition suitable for emulsification of whey protein nutrition composition and its combination, so that whey protein nutrition composition with good emulsification stability after heat sterilization treatment. I found out I could get something.
That is, this invention is shown to the following (1)-(5).
(1) A nutritional composition containing whey protein, lipids, sugars, vitamins and minerals, containing the following (A) and (B) as emulsifiers, and (A) emulsifier (B 0.5-3 parts by weight of whey protein nutritional composition which is liquid after heat sterilization.
(A) one or more organic acid monoglycerides selected from the group consisting of glyceryl monostearate succinate, glyceryl monostearate lactate, glyceryl monostearate diacetyl tartrate,
(B) Polyglycerin fatty acid ester having an HLB value of 12 to 14 and a melting point of the fatty acid constituting the emulsifier of 60 ° C. or lower.
(2) The whey protein nutrition composition according to (1) above, wherein the average particle size of fat globules in the preparation after heat sterilization is 0.4 μm or less.
(3) The whey protein nutrition composition according to (1) or (2) above, wherein the emulsifier selected from (B) is decaglycerin monomyristate and / or decaglycerin monooleate.
(4) The whey protein nutrition composition according to any one of (1) to (3) above, wherein the heat sterilization method is retort sterilization or UHT sterilization.
(5) The whey protein nutrition composition according to any one of (1) to (4), wherein the viscosity after heat sterilization is 30 mPa · s or less at room temperature.
以上述べたように、本発明は、たんぱく質、糖質、脂質、ビタミン、ミネラル等からなる栄養組成物において、脂質、たんぱく質を乳清たんぱく質として含有することを特徴とする、加熱殺菌処理された、乳清たんぱく栄養組成物を提供することができる。 As described above, the present invention is a nutritional composition composed of protein, carbohydrate, lipid, vitamin, mineral, etc., characterized by containing lipid, protein as whey protein, and heat-sterilized. A whey protein nutritional composition can be provided.
以下、本発明の栄養組成物を詳細に説明する。
本発明における乳清たんぱくの原料となる乳は、牛、ヤギ、ヒツジ、馬等いずれの哺乳類の乳も使用できる。乳清たんぱくは、従来の方法によって製造されるものが使用でき、チーズホエイ、酸ホエイ等の乳清から製造したたんぱく質を用いることができる。その場合の製造方法としては、制限はない。例えば、製造方法としては、スプレードライ、真空濃縮法、電気透析法、イオン交換法、クロマトグラフィー法、結晶化、あるいは、膜技術を利用した浸透膜法、逆浸透法、限外濾過法、精密濾過法、極微濾過法、ナノフィルトレーション等の加工法、その他いずれの方法によるものでも使用できる。また、乳糖を除去させる方法も併用してよい。本発明における乳清たんぱくとしては、市販されている脱乳糖ホエイ、低乳糖ホエイ、脱塩ホエイ、乳清たんぱく濃縮物(WPC)、乳清たんぱく単離物(WPI)、α−ラクトアルブミン、β−ラクトグロブリン等これらの中から1種類以上ないし数種類の原料の組み合わせて用いることができるが、好ましくは原料の最終乾燥製品におけるたんぱく質含量が70%以上であるWPCを使用する。
本発明に使用することのできる乳清たんぱくとして、具体的には、Lacprodan DI−8702(アーラフーズイングレディエンツジャパン株式会社)、Calpro WPC8002(メグレ・ジャパン株式会社)があげられる。
Hereinafter, the nutritional composition of the present invention will be described in detail.
The milk used as the raw material for the whey protein in the present invention may be milk of any mammal such as cow, goat, sheep and horse. As the whey protein, those produced by conventional methods can be used, and proteins produced from whey such as cheese whey and acid whey can be used. There is no restriction on the manufacturing method in that case. For example, the production method includes spray drying, vacuum concentration method, electrodialysis method, ion exchange method, chromatography method, crystallization, or osmosis membrane method using membrane technology, reverse osmosis method, ultrafiltration method, precision A filtration method, a microfiltration method, a processing method such as nanofiltration, or any other method can be used. Moreover, you may use together the method of removing lactose. As whey protein in the present invention, commercially available delactose whey, low lactose whey, desalted whey, whey protein concentrate (WPC), whey protein isolate (WPI), α-lactalbumin, β -It can be used in combination of one or more or several kinds of raw materials such as lactoglobulin, but preferably WPC having a protein content of 70% or more in the final dry product of the raw materials is used.
Specific examples of whey proteins that can be used in the present invention include Lacprodan DI-8702 (Arrah's Ingredients Japan Co., Ltd.) and Calpro WPC8002 (Megure Japan Co., Ltd.).
本発明における脂質は、一般に食用として利用される脂質を使用することができる。例えば、アマニ油、エゴマ油、オリーブ油、ごま油、米ぬか油、サフラワー油、シソ油、大豆油、とうもろこし油、ナタネ油、胚芽油、パーム油、パーム核油、ひまわり油、綿実油、やし油、落花生油等の植物性油脂、魚油、乳脂等の動物性油脂、中鎖脂肪酸、高度不飽和脂肪酸等の脂質を単独または混合して使用できる。その他にDHA、EPA、ジアシルグリセロール等の加工製剤も添加することができる。
本発明における乳化剤(A)としては、コハク酸グリセリンモノステアレート、乳酸グリセリンモノステアレート、ジアセチル酒石酸グリセリンモノステアレートが使用できる。これら有機酸モノグリセリドは、主にモノグリセリドに有機酸をエステル結合させ、親水性を向上させる等機能を改善した誘導体を言い、本発明では有機酸モノグリセリドとしては、有機酸として乳酸を結合させた乳酸モノグリセリド、ジアセチル酒石酸を結合させたジアセチル酒石酸モノグリセリド、コハク酸を結合させたコハク酸モノグリセリドのいずれか1つ以上が用いられる。
上記有機酸モノグリセリドは、最終製品中で、0.05〜0.4重量%、好ましくは0.15〜0.3重量%を使用する。0.05重量%未満では乳化が困難となり、0.4重量%より多いと解乳化が引き起こされがちになる。
As lipids in the present invention, lipids generally used for food can be used. For example, linseed oil, sesame oil, olive oil, sesame oil, rice bran oil, safflower oil, perilla oil, soybean oil, corn oil, rapeseed oil, germ oil, palm oil, palm kernel oil, sunflower oil, cottonseed oil, palm oil, Vegetable fats and oils such as peanut oil, animal fats and oils such as fish oil and milk fat, lipids such as medium chain fatty acids and highly unsaturated fatty acids can be used alone or in combination. In addition, processed preparations such as DHA, EPA, diacylglycerol and the like can be added.
As the emulsifier (A) in the present invention, glyceryl monostearate succinate, glyceryl monostearate lactate, and glyceryl monostearate diacetyl tartrate can be used. These organic acid monoglycerides mainly refer to derivatives that have improved functions such as ester bonding of an organic acid to monoglyceride to improve hydrophilicity. In the present invention, the organic acid monoglyceride is a lactic acid monoglyceride in which lactic acid is bound as an organic acid. Any one or more of diacetyltartaric acid monoglyceride combined with diacetyltartaric acid and succinic acid monoglyceride combined with succinic acid are used.
The organic acid monoglyceride is used in the final product in an amount of 0.05 to 0.4% by weight, preferably 0.15 to 0.3% by weight. If it is less than 0.05% by weight, emulsification becomes difficult, and if it exceeds 0.4% by weight, demulsification tends to be caused.
本発明における乳化剤(B)としては、ポリグリセリン脂肪酸エステルを使用する。この場合、ポリグリセリン脂肪酸エステルのHLB値は12〜14であるものが好ましい。HLBが12より低いと親水性に乏しくなるため、乳化安定性を付与することが難しくなり、HLBが14より高いと可溶化力が強くなるため、乳化にとって好ましくない。
本発明におけるHLB(Hydrophilic Lipophilic Balance)値は、通常界面活性剤の分野で使用される親水性‐疎水性のバランスをいい、一般的に用いられている計算式や実験的手法を使用して算出する。例えば、Griffin法、Davies法、川上法、アトラス法が挙げられる。またこれらの方法に限らず、市販品のカタログ等に記載されているHLB値の数値を使用してもよい。
最も好ましくは、以下の式(1)に表した、川上法を使用する。
なお、後述の実施例におけるHLB値は、以下に記載の川上法に則り算出した値を記載した。
HLB=7+11.7log10(Mw/Mo)・・・・・(1)
Mw:親水基の分子量、Mo:親油基の分子量
As the emulsifier (B) in the present invention, polyglycerin fatty acid ester is used. In this case, the polyglycerol fatty acid ester preferably has an HLB value of 12-14. If the HLB is lower than 12, the hydrophilicity becomes poor, so that it is difficult to impart emulsification stability. If the HLB is higher than 14, the solubilizing power is increased, which is not preferable for emulsification.
The HLB (Hydrophilic Lipophilic Balance) value in the present invention refers to the hydrophilic-hydrophobic balance usually used in the field of surfactants, and is calculated using commonly used calculation formulas and experimental methods. To do. Examples include the Griffin method, the Davies method, the Kawakami method, and the Atlas method. Moreover, you may use the numerical value of the HLB value described not only in these methods but in the catalog of a commercial item.
Most preferably, the Kawakami method represented by the following formula (1) is used.
In addition, the HLB value in the Example mentioned later described the value calculated according to the Kawakami method described below.
HLB = 7 + 11.7log 10 (Mw / Mo) (1)
Mw: molecular weight of hydrophilic group, Mo: molecular weight of lipophilic group
また、このポリグリセリン脂肪酸エステルは、構成する脂肪酸の融点が60℃以下である。構成する脂肪酸の融点が60℃を超えると、本発明の乳清たんぱく栄養組成物の調製時に乳清たんぱくが62℃で熱変性が開始し、疎水的相互作用に起因したSH/SS交換反応を伴う変性が生じるため好ましくない。
本発明では、(A)の乳化剤の1重量部に対して、(B)より選ばれる乳化剤0.5〜3重量部を使用するのが好ましい。
なお、本発明の目的を逸脱しない範囲において、上記の乳化剤以外に加えて汎用される乳化剤を追加して使用することができる。
Moreover, this polyglycerin fatty acid ester has a melting point of the constituent fatty acid of 60 ° C. or lower. When the melting point of the constituent fatty acid exceeds 60 ° C, the whey protein starts to denature at 62 ° C during the preparation of the whey protein nutrition composition of the present invention, and the SH / SS exchange reaction caused by the hydrophobic interaction is caused. This is not preferable because the accompanying modification occurs.
In this invention, it is preferable to use 0.5-3 weight part of emulsifiers selected from (B) with respect to 1 weight part of the emulsifier of (A).
In addition, in addition to the above-mentioned emulsifier, a general-purpose emulsifier can be added and used within a range not departing from the object of the present invention.
本発明における糖質は、各種の糖質が配合される。このような糖質としては、例えばデンプン、デキストリン、マルトデキストリン等が挙げられる。より好ましくは分解度の低いデキストリンを使用し、浸透圧性の下痢を予防する。DE値(Dextrose Equivalent)8〜25の範囲にあるものが好ましく、この範囲にあれば、流動性も確保でき、浸透圧についても十分低くすることができる。また、クラスターデキストリンやシクロデキストリンも添加することができる。このほかにも糖質としては、グルコース、果糖もしくはガラクトース、キシリトール、糖アルコール、アラビノース、イノシトール、ソルビトール等の単糖類、ショ糖、乳糖、麦芽糖、トレハロース、パラチノース等の二糖類を一部配合することも可能である。
また、腸内環境改善を目的として、フラクトオリゴ糖、乳果オリゴ糖、イソマルトオリゴ糖、ラクチュロース等を添加することも可能である。
Various saccharides are blended in the saccharide in the present invention. Examples of such saccharides include starch, dextrin, and maltodextrin. More preferably, dextrin having a low degree of degradation is used to prevent osmotic diarrhea. What is in the range of DE value (Dextrose Equivalent) 8-25 is preferable, if it exists in this range, fluidity | liquidity can also be ensured and osmotic pressure can also be made low enough. Moreover, cluster dextrin and cyclodextrin can also be added. In addition to this, as sugars, monosaccharides such as glucose, fructose or galactose, xylitol, sugar alcohol, arabinose, inositol, sorbitol, disaccharides such as sucrose, lactose, maltose, trehalose, palatinose, etc. Is also possible.
Further, for the purpose of improving the intestinal environment, fructooligosaccharides, dairy oligosaccharides, isomaltoligosaccharides, lactulose and the like can be added.
本発明におけるビタミンとしては、ビタミンA、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK、ナイアシン、パントテン酸、葉酸、ビオチン等が使用でき、これらを1種類単独で用いてもよいが、2種類以上配合して使用しても良い。
本発明におけるミネラルとしては、ナトリウム、カルシウム、カリウム、マグネシウム、鉄、リン、銅、亜鉛、塩素等が挙げられ、これら複数をできる限り組み合わせて配合するのが好ましい。本発明で使用する化合物としては、従来から食品に慣用されるものでよく、例えば、塩化カルシウム、クエン酸カルシウム、グリセロリン酸カルシウム、グルコン酸カルシウム、水酸化カルシウム、ステアリン酸カルシウム、ステアロイル乳酸カルシウム、炭酸カルシウム、乳酸カルシウム、ピロリン酸二水素カルシウム、硫酸カルシウム、リン酸三カルシウム、リン酸一水素カルシウム、リン酸二水素カルシウム、未焼成カルシウム、塩化マグネシウム、ステアリン酸マグネシウム、炭酸マグネシウム、硫酸マグネシウム、リン酸三マグネシウム、塩化第二鉄、クエン酸第一鉄ナトリウム、クエン酸鉄、クエン酸鉄アンモニウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第二鉄、硫酸第一鉄、グルコン酸亜鉛、硫酸亜鉛、グルコン酸銅、硫酸銅等が挙げられる。
As vitamins in the present invention, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, niacin, pantothenic acid, folic acid, biotin, etc. can be used. One type may be used alone, or two or more types may be blended and used.
Examples of the mineral in the present invention include sodium, calcium, potassium, magnesium, iron, phosphorus, copper, zinc, chlorine, and the like. The compounds used in the present invention may be those conventionally used in foods, for example, calcium chloride, calcium citrate, calcium glycerophosphate, calcium gluconate, calcium hydroxide, calcium stearate, stearoyl calcium lactate, calcium carbonate, Calcium lactate, calcium dihydrogen pyrophosphate, calcium sulfate, tricalcium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, uncalcined calcium, magnesium chloride, magnesium stearate, magnesium carbonate, magnesium sulfate, trimagnesium phosphate , Ferric chloride, sodium ferrous citrate, iron citrate, ammonium iron citrate, ferrous gluconate, iron lactate, ferric pyrophosphate, ferrous sulfate, zinc gluconate, zinc sulfate, glucone Acid copper, sulfur Copper and the like.
上記に挙げたミネラル以外にもヨウ素、セレン、クロム、モリブデン、マンガン等の有機塩、無機塩または酵母の形態で配合することができる。分散性を高めるために乳化液やスラリーとした製剤を使用してもよい。
本発明では上記の有効成分以外にも各種の栄養成分を配合することができる。このような栄養成分としては、上記以外のビタミン類やミネラル類等が挙げられる。
本発明は、更に乳化安定性を付与するために、増粘多糖類、乳化安定剤を併用することが望ましい。また、本発明では食物繊維を配合してもよい。
本発明はこれらに限定されるものではなく、必要に応じて他の成分類や添加剤等を添加してもよい。例えば、クエン酸、酒石酸、リンゴ酸、コハク酸、グルコン酸、フマル酸、乳酸、グリセリン、高甘味度甘味料、酸味料、調味料、カラメル、エキス、pH調整剤、プロピレングリコール脂肪酸エステル、アラビアゴム、色素、香料、保存剤、静菌剤等、通常の食品原料として使用されている添加剤等を適宜添加してもよい。
本発明において製造に際しては上記に説明した組成範囲に基づいて更に、後述の実施例や栄養組成物の製造法として従来から知られている方法、もしくは今後新しく提供される方法を利用すれば、本発明で目的とする乳清たんぱく栄養組成物を製造することができる。
In addition to the minerals listed above, they can be blended in the form of organic salts such as iodine, selenium, chromium, molybdenum, manganese, inorganic salts, or yeast. In order to enhance dispersibility, a preparation in the form of an emulsion or slurry may be used.
In the present invention, various nutritional components can be blended in addition to the above active ingredients. Examples of such nutritional components include vitamins and minerals other than those described above.
In the present invention, it is desirable to use a thickening polysaccharide and an emulsion stabilizer in combination in order to further impart emulsion stability. Moreover, in this invention, you may mix | blend a dietary fiber.
This invention is not limited to these, You may add another component, an additive, etc. as needed. For example, citric acid, tartaric acid, malic acid, succinic acid, gluconic acid, fumaric acid, lactic acid, glycerin, high-intensity sweetener, acidulant, seasoning, caramel, extract, pH adjuster, propylene glycol fatty acid ester, gum arabic Additives used as usual food ingredients such as pigments, fragrances, preservatives and bacteriostatic agents may be added as appropriate.
In the production of the present invention, based on the composition range described above, if a method conventionally known as a production method of Examples and nutritional compositions described later, or a method newly provided in the future is used, The intended whey protein nutritional composition of the invention can be produced.
本発明における均質化とは、水と油とを含む混合液をエマルションとし、さらにエマルションの液滴を微粒化することである。均質化の一つの方法としては、例えば、回転羽を有する攪拌機、高速回転するディスクやローターと固定ディスクを有するコロイドミル、超音波式乳化機、一種の高圧ポンプである均質機(ホモジナイザー)等が挙げられる。
本発明における乳清たんぱく栄養組成物は、容器等に充填された状態にあるものも含まれ、その場合、製剤を予め加熱滅菌した後に無菌的に容器に充填する方法(例えばUHT殺菌法とアセプティック充填法を併用する方法)、あるいは容器に充填した後に容器と一緒に加熱滅菌する方法(レトルト殺菌法)を採用することができる。なお、UHT殺菌法では飲料に直接水蒸気を吹き込むスチームインジェクション式や飲料を水蒸気中に噴射して加熱するスチームインフュージョン式等の直接加熱方式、プレートやチューブ等、表面熱交換機器を用いる間接加熱方式等の公知の方法で行うことができる。いずれの殺菌方式においても130〜150℃、2〜60秒程度の加熱処理が好ましい。レトルト殺菌の場合、110〜120℃、4〜30分程度の加熱処理が好ましい。
本発明で得られた乳清たんぱく栄養組成物を収容する容器としては特に限定されないが、患者が摂取しやすい形態であることが好ましい。
The homogenization in the present invention is to make a mixed liquid containing water and oil into an emulsion and further atomize the droplets of the emulsion. As one method of homogenization, for example, a stirrer having a rotating blade, a colloid mill having a disk rotating at high speed or a rotor and a fixed disk, an ultrasonic emulsifier, a homogenizer which is a kind of high-pressure pump (homogenizer), etc. Can be mentioned.
The whey protein nutritional composition in the present invention includes those in a state of being filled in a container or the like. In that case, a method of filling the container aseptically after pre-sterilizing the preparation (for example, UHT sterilization method and aseptic) It is possible to employ a method in which a filling method is used in combination, or a method of heating and sterilizing together with the container after filling the container (retort sterilization method). In addition, in the UHT sterilization method, a direct injection method such as a steam injection method in which water vapor is directly blown into the beverage or a steam infusion method in which the beverage is heated by being injected into the water vapor, an indirect heating method using a surface heat exchange device such as a plate or tube It can carry out by well-known methods, such as. In any sterilization method, heat treatment at 130 to 150 ° C. for about 2 to 60 seconds is preferable. In the case of retort sterilization, heat treatment at 110 to 120 ° C. for about 4 to 30 minutes is preferable.
Although it does not specifically limit as a container which accommodates the whey protein nutrition composition obtained by this invention, It is preferable that it is a form which a patient can ingest easily.
使用する容器としては、軟質合成樹脂(例えば可塑化塩化ビニル樹脂、ポリウレタン系樹脂、ポリエチレン系樹脂、ポリプロピレン系樹脂、エチレン−酢酸ビニル共重合体、エチレン−α−オレフィン共重合体等の各種ポリオレフィン系樹脂、ポリフルオロカーボン、ポリイミド等)により形成された密閉型であり、加熱殺菌可能な軟質容器が好適である。また、紙にアルミ箔、更に容器の内表面側に合成樹脂(例えばポリエチレン)をラミネートした素材により形成された容器等も使用することができ、このラミネート容器は、アセプティック包装法に好適である。
その他にも、医療用容器等に使用されている樹脂を適宜使用することができる。ポリエチレンテレフタレート(PET)、ポリエチレンナフタレート(PEN)、エチレン・ビニルアルコール共重合体(EVOH)、ポリ塩化ビニリデン(PVDC)、ポリアクリロニトリル、ポリビニルアルコール、ポリアミド、ポリエステル等のガスバリア性樹脂層や、アルミ箔、アルミ蒸着フィルム、酸化珪素皮膜、酸化アルミ被膜等のガスバリア性を有する層を、なお、容器に透明性を要求されるときはこれらのうち透明なものを選んで、上記した軟質合成樹脂に必要により適宜組み合わせて、フィルムの層成分として用いることが好ましい。
As a container to be used, a soft synthetic resin (for example, a plasticized vinyl chloride resin, a polyurethane resin, a polyethylene resin, a polypropylene resin, an ethylene-vinyl acetate copolymer, an ethylene-α-olefin copolymer, or other polyolefin-based resins). A sealed container formed of a resin, polyfluorocarbon, polyimide, etc.) and heat sterilizable is preferable. Moreover, a container formed of a material obtained by laminating a paper and an aluminum foil and a synthetic resin (for example, polyethylene) on the inner surface side of the container can also be used. This laminated container is suitable for the aseptic packaging method.
In addition, resins used in medical containers and the like can be used as appropriate. Gas barrier resin layers such as polyethylene terephthalate (PET), polyethylene naphthalate (PEN), ethylene-vinyl alcohol copolymer (EVOH), polyvinylidene chloride (PVDC), polyacrylonitrile, polyvinyl alcohol, polyamide, polyester, and aluminum foil , Layer with gas barrier properties such as aluminum vapor deposition film, silicon oxide film, aluminum oxide film, etc. If the container is required to be transparent, choose a transparent one of these, and it is necessary for the above soft synthetic resin It is preferable to use as a layer component of a film combining suitably.
本発明において液状とは、加熱殺菌された後に、乳清たんぱく栄養組成物の粘度が30mPa・s以下の状態を意味する。
粘度の測定は、第7版食品添加物公定書 B.一般試験法 28.粘度測定法 第2法 回転粘度計法で行う。例えば、RB80L形粘度計(東機産業株式会社)を用いて測定した値をいう。以下の実施例においては、本粘度計を用いて測定した値を記した。
このように調製された乳清たんぱく栄養組成物は、水中油型の乳化物等であって、この脂肪球の平均粒径は0.4μm未満であることが好ましい。ここでいう、平均粒径は、レーザー回折型粒度分布計SALD−300V(株式会社島津製作所)や、透過型粒度分布計ZETASIZER3000HS(MALVERN社)で測定した値をいう。
このようにして得られた乳清たんぱく栄養組成物は、患者への栄養補給の際に使用される。その投与形態としては、状況に応じて経口または経管にて投与することができる。
In the present invention, the liquid state means a state in which the whey protein nutrition composition has a viscosity of 30 mPa · s or less after being heat-sterilized.
Viscosity is measured according to the 7th edition Food Additives Official Document. General test method 28. Viscosity measurement method Method 2 Rotational viscometer method is used. For example, it refers to a value measured using an RB80L viscometer (Toki Sangyo Co., Ltd.). In the following examples, values measured using the viscometer were described.
The whey protein nutrition composition thus prepared is an oil-in-water emulsion or the like, and the average particle size of the fat globules is preferably less than 0.4 μm. Here, the average particle diameter refers to a value measured with a laser diffraction type particle size distribution analyzer SALD-300V (Shimadzu Corporation) or a transmission type particle size distribution analyzer ZETASIZER 3000HS (MALVERN).
The whey protein nutritional composition thus obtained is used for nutritional supplementation to patients. The dosage form can be administered orally or by tube depending on the situation.
また、本乳清たんぱく栄養組成物は、嚥下障害が見られる場合や胃ろうへの投与を行う場合等には、必要に応じて糊料(増粘剤、ゲル化剤)を添加して粘体状またはゼリー状に調製することもできる。
本発明の乳清たんぱく栄養組成物は、年齢や症状等により異なるが、通常の食事の摂取が困難な場合には、ヒト成人一人あたり一日1200kcal〜2000kcalを経口的または経管・経腸的に投与することが好ましい。また、補食的に通常の食事と併用することも可能である。
In addition, this whey protein nutritional composition can be used by adding a paste (thickener, gelling agent) as necessary when swallowing disorders are observed or when it is administered to the gastric fistula. It can also be prepared in the form of a gel or jelly.
The whey protein nutritional composition of the present invention varies depending on age, symptoms, etc., but when it is difficult to take a normal meal, 1200 kcal to 2000 kcal per day for each human adult is administered orally or enterally or enterally. Is preferably administered. It can also be used in combination with a normal meal as a supplement.
以下に本発明の実施例を示すが、これらの例に限られたものではない。
(実施例1)
表1に示す配合に基づき、調製法1の方法により乳清たんぱく栄養組成物を調製した。得られた乳清たんぱく栄養組成物の粘度は6.0mPa・sであった。
Examples of the present invention are shown below, but are not limited to these examples.
Example 1
Based on the formulation shown in Table 1, a whey protein nutrition composition was prepared by the method of Preparation Method 1. The viscosity of the obtained whey protein nutrition composition was 6.0 mPa · s.
(調製法1)
40℃の温水6Lを攪拌しながら、リン酸三ナトリウム、塩化カルシウム、酸化マグネシウム、乳清たんぱくとしてCalpro WPC8002(メグレ・ジャパン株式会社)を少しずつ加え、十分に溶解させた後、乳化剤(B)としてデカグリセリンモノミリステート(サンソフトQ−14S、太陽化学株式会社)、デキストリンとしてサンデック#250(三和澱粉工業株式会社)、塩化カリウム、クエン酸鉄、グルコン酸銅、グルコン酸亜鉛を加えて十分に攪拌し水相とした。加温した大豆油に乳化剤(A)として乳酸グリセリンモノステアレート(サンソフトNo.661AS、太陽化学株式会社)を投入し、溶解させて油相とした。60℃に昇温した水相に油相を混合し、プロペラ攪拌機により5分間の予備乳化を行い、原料溶液を得た。その後、該原料溶液を高圧均質機を使用し、70MPaの圧力で均質化処理した。均質化処理後、得られた乳化液に、適量の水に溶解させ水溶液としたビタミンミックス、アスコルビン酸ナトリウム水溶液、ピーチエッセンスを添加し混合し、さらに水を加えて全量を10Lとした。これをレトルトパウチ(大日本印刷株式会社)に200mLずつ充填し、密封し、120℃、20分のレトルト殺菌処理を実施し、乳清たんぱく栄養組成物を得た。
(Preparation method 1)
While stirring 6 L of warm water of 40 ° C., Calpro WPC8002 (Megure Japan Co., Ltd.) was added little by little as trisodium phosphate, calcium chloride, magnesium oxide and whey protein, and after sufficient dissolution, emulsifier (B) As decaglycerin monomyristate (Sunsoft Q-14S, Taiyo Kagaku Co., Ltd.), as dextrin, add Sandeck # 250 (Sanwa Starch Co., Ltd.), potassium chloride, iron citrate, copper gluconate, zinc gluconate The mixture was sufficiently stirred to obtain an aqueous phase. Lactic acid glycerin monostearate (Sunsoft No. 661AS, Taiyo Kagaku Co., Ltd.) was added to the heated soybean oil as an emulsifier (A) and dissolved to obtain an oil phase. The oil phase was mixed with the aqueous phase heated to 60 ° C., and pre-emulsified for 5 minutes with a propeller stirrer to obtain a raw material solution. Thereafter, the raw material solution was homogenized at a pressure of 70 MPa using a high-pressure homogenizer. After the homogenization treatment, the resulting emulsion was dissolved in an appropriate amount of water and mixed with an aqueous solution of vitamin mix, aqueous sodium ascorbate, and peach essence, and water was added to make the total volume 10 L. Retort pouches (Dai Nippon Printing Co., Ltd.) were filled with 200 mL each, sealed, and subjected to a retort sterilization treatment at 120 ° C. for 20 minutes to obtain a whey protein nutrition composition.
(実施例2)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレートをコハク酸グリセリンモノステアレート(サンソフトNo.681NU、太陽化学株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.6mPa・sであった。
(実施例3)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレートをジアセチル酒石酸グリセリンモノステアレート(ポエムW−10、理研ビタミン株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は6.8mPa・sであった。
(実施例4)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレート15g/10Lを5g/10Lに変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.9mPa・sであった。
(実施例5)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレート15g/10Lを20g/10Lに変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は6.0mPa・sであった。
(Example 2)
In Example 1, exactly the same preparation method as Example 1 was repeated except that the glyceryl glycerol monostearate of the emulsifier (A) was changed to glyceryl succinate monostearate (Sunsoft No. 681NU, Taiyo Kagaku Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 5.6 mPa · s.
(Example 3)
In Example 1, the same preparation method as in Example 1 was repeated except that the glyceryl monostearate of emulsifier (A) was changed to glyceryl monostearate diacetyl tartrate (Poem W-10, Riken Vitamin Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 6.8 mPa · s.
Example 4
A whey protein nutritional composition was obtained by repeating exactly the same preparation method as in Example 1, except that 15 g / 10 L of lactic acid glycerin monostearate of the emulsifier (A) was changed to 5 g / 10 L in Example 1. The viscosity of the obtained whey protein nutrition composition was 5.9 mPa · s.
(Example 5)
A whey protein nutrition composition was obtained by repeating exactly the same preparation method as in Example 1 except that 15 g / 10 L of lactic acid glycerin monostearate of the emulsifier (A) was changed to 20 g / 10 L in Example 1. The viscosity of the obtained whey protein nutrition composition was 6.0 mPa · s.
(比較例1)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレートをクエン酸グリセリンモノステアレート(サンソフトNo.621G、太陽化学株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は6.2mPa・sであった。
(比較例2)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレートをグリセリンモノステアレート(サンソフトNo.8004、太陽化学株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.2mPa・sであった。
(比較例3)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレートをコハク酸グリセリンモノオレエート(サンソフトNo.683CB、太陽化学株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.2mPa・sであった。
(比較例4)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレートをグリセリンモノオレエート(サンソフトNo.8070V、太陽化学株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.9mPa・sであった。
(比較例5)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレート15g/10Lを3g/10Lに変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.9mPa・sであった。
(比較例6)
実施例1において、乳化剤(A)の乳酸グリセリンモノステアレート15g/10Lを25g/10Lに変えた以外は、実施例1と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は6.0mPa・sであった。
(Comparative Example 1)
In Example 1, exactly the same preparation method as Example 1 was repeated except that the glyceryl glycerol monostearate of the emulsifier (A) was changed to glyceryl glycerol monostearate (Sunsoft No. 621G, Taiyo Kagaku Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutritional composition was 6.2 mPa · s.
(Comparative Example 2)
In Example 1, the same preparation method as in Example 1 was repeated except that the lactic acid glycerol monostearate of the emulsifier (A) was changed to glycerol monostearate (Sunsoft No. 8004, Taiyo Kagaku Co., Ltd.). A clean protein nutritional composition was obtained. The viscosity of the obtained whey protein nutritional composition was 5.2 mPa · s.
(Comparative Example 3)
In Example 1, exactly the same preparation method as Example 1 was repeated except that the glyceryl monostearate of the emulsifier (A) was changed to glyceryl monosoleate succinate (Sunsoft No. 683CB, Taiyo Kagaku Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutritional composition was 5.2 mPa · s.
(Comparative Example 4)
In Example 1, the same preparation method as in Example 1 was repeated except that the lactic acid glycerol monostearate of the emulsifier (A) was changed to glycerol monooleate (Sunsoft No. 8070V, Taiyo Kagaku Co., Ltd.). A clean protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 4.9 mPa · s.
(Comparative Example 5)
A whey protein nutrition composition was obtained by repeating exactly the same preparation method as in Example 1, except that 15 g / 10 L of lactic acid glycerol monostearate as the emulsifier (A) was changed to 3 g / 10 L in Example 1. The viscosity of the obtained whey protein nutrition composition was 5.9 mPa · s.
(Comparative Example 6)
A whey protein nutrition composition was obtained by repeating exactly the same preparation method as in Example 1 except that 15 g / 10 L of lactic acid glycerin monostearate of the emulsifier (A) was changed to 25 g / 10 L in Example 1. The viscosity of the obtained whey protein nutrition composition was 6.0 mPa · s.
(評価法1)
実施例1から5と比較例1から6の乳清たんぱく栄養組成物の調製直後および60℃に7日間保存した後の状態を観察し、回折型粒度分布計SALD−300Vで平均粒径を測定した。結果を表3に示す。乳化剤(A)の種類を変えた実施例1から3の乳清たんぱく栄養組成物の調製直後および60℃に7日間保存した後の状態は、いずれも均一な液状であり、平均粒径は、いずれも0.4μm以下であった。一方、実施例1の乳化剤(A)の種類を変えた比較例1から4の乳清たんぱく栄養組成物の調製直後の状態は、いずれも均一な液状であったが、60℃に7日間保存した後の状態は、クリーミングまたはオイルオフを発生し、平均粒径は0.4μmより大きくなった。また、実施例1の乳化剤(A)の配合量を変えた実施例4および5の乳清たんぱく栄養組成物の調製直後および60℃に7日間保存した後の状態は、いずれも均一な液状であり、平均粒径は、いずれも0.4μm以下であった。一方、実施例1の乳化剤(A)の配合量を変えた比較例5および6の乳清たんぱく栄養組成物の調製直後の状態は、いずれも均一な液状であったが、60℃に7日間保存した後の状態は、クリーミングを発生し、平均粒径は0.4μmより大きくなった。
(Evaluation method 1)
The state immediately after the preparation of the whey protein nutritional compositions of Examples 1 to 5 and Comparative Examples 1 to 6 and after storage at 60 ° C. for 7 days was observed, and the average particle size was measured with a diffraction type particle size distribution analyzer SALD-300V did. The results are shown in Table 3. The state immediately after the preparation of the whey protein nutrition composition of Examples 1 to 3 in which the type of the emulsifier (A) was changed and after being stored at 60 ° C. for 7 days were all in a uniform liquid state, All were 0.4 μm or less. On the other hand, the state immediately after the preparation of the whey protein nutrition composition of Comparative Examples 1 to 4 in which the type of emulsifier (A) of Example 1 was changed was a uniform liquid, but was stored at 60 ° C. for 7 days. In the condition after the treatment, creaming or oil-off occurred, and the average particle size became larger than 0.4 μm. Moreover, the state immediately after preparation of the whey protein nutrition composition of Example 4 and 5 which changed the compounding quantity of the emulsifier (A) of Example 1 and after storing for 7 days at 60 degreeC is a uniform liquid state. The average particle size was 0.4 μm or less. On the other hand, the state immediately after the preparation of the whey protein nutrition composition of Comparative Examples 5 and 6 in which the blending amount of the emulsifier (A) of Example 1 was changed was a uniform liquid, but at 60 ° C. for 7 days. The state after storage caused creaming and the average particle size was larger than 0.4 μm.
(実施例6)
表4に示す配合に基づき、調製法2の方法により乳清たんぱく栄養組成物を調製した。得られた乳清たんぱく栄養組成物の粘度は4.5mPa・sであった。
(Example 6)
Based on the formulation shown in Table 4, a whey protein nutritional composition was prepared by the method of Preparation Method 2. The viscosity of the obtained whey protein nutrition composition was 4.5 mPa · s.
(調製法2)
40℃の温水6Lを攪拌しながら、リン酸三ナトリウム、塩化カルシウム、酸化マグネシウム、乳清たんぱくとしてLacprodan DI−8072(アーラフーズイングレディエンツジャパン株式会社)を少しずつ加え、十分に溶解させた後、乳化剤(B)としてデカグリセリンモノオレエート(SYグリスターMO−7S、阪本薬品工業株式会社)、デキストリンとしてTK−16(松谷化学工業株式会社)、塩化カリウム、クエン酸鉄、グルコン酸銅、グルコン酸亜鉛を加えて十分に攪拌し水相とした。加温した大豆油に乳化剤(A)として乳酸グリセリンモノステアレート(サンソフトNo.661AS、太陽化学株式会社)を投入し、溶解させて油相とした。60℃に昇温した水相に油相を混合し、プロペラ攪拌機により5分間の予備乳化を行い、原料溶液を得た。その後、該原料溶液を高圧均質機を使用し、70MPaの圧力で均質化処理した。均質化処理後、得られた乳化液に、適量の水に溶解させ水溶液としたビタミンミックス、アスコルビン酸ナトリウム水溶液、ウメエッセンスを添加し混合し、さらに水を加えて全量を10Lとした。これをレトルトパウチ(大日本印刷株式会社)に200mLずつ充填し、密封し、120℃、20分のレトルト殺菌処理を実施し、乳清たんぱく栄養組成物を得た。
(Preparation method 2)
While stirring 6 L of warm water at 40 ° C., Lacprodan DI-8072 (Arrah's Ingredients Japan Co., Ltd.) was added little by little as trisodium phosphate, calcium chloride, magnesium oxide and whey protein and dissolved sufficiently. , Decaglycerin monooleate (SY Glyster MO-7S, Sakamoto Yakuhin Kogyo Co., Ltd.) as emulsifier (B), TK-16 (Matsuya Chemical Co., Ltd.) as dextrin, potassium chloride, iron citrate, copper gluconate, glucone Zinc acid was added and stirred well to obtain an aqueous phase. Lactic acid glycerin monostearate (Sunsoft No. 661AS, Taiyo Kagaku Co., Ltd.) was added to the heated soybean oil as an emulsifier (A) and dissolved to obtain an oil phase. The oil phase was mixed with the aqueous phase heated to 60 ° C., and pre-emulsified for 5 minutes with a propeller stirrer to obtain a raw material solution. Thereafter, the raw material solution was homogenized at a pressure of 70 MPa using a high-pressure homogenizer. After the homogenization treatment, the resulting emulsion was dissolved in an appropriate amount of water and mixed with a vitamin mix, an aqueous solution of sodium ascorbate, and a ume essence, and further mixed with water to make a total volume of 10L. Retort pouches (Dai Nippon Printing Co., Ltd.) were filled with 200 mL each, sealed, and subjected to a retort sterilization treatment at 120 ° C. for 20 minutes to obtain a whey protein nutrition composition.
(実施例7)
実施例6において、乳化剤(A)の乳酸グリセリンモノステアレートをコハク酸グリセリンモノステアレート(サンソフトNo.681NU、太陽化学株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.3mPa・sであった。
(実施例8)
実施例6において、乳化剤(A)の乳酸グリセリンモノステアレートをジアセチル酒石酸グリセリンモノステアレート(ポエムW−10、理研ビタミン株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.0mPa・sであった。
(実施例9)
実施例7において、乳化剤(B)のデカグリセリンモノオレエート10g/10Lを20g/10Lに変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.3mPa・sであった。
(実施例10)
実施例7において、乳化剤(B)のデカグリセリンモノオレエート10g/10Lを30g/10Lに変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.3mPa・sであった。
(実施例11)
実施例7において、乳化剤(B)のデカグリセリンモノオレエート10g/10Lを40g/10Lに変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.3mPa・sであった。
(Example 7)
In Example 6, the same preparation method as in Example 6 was repeated except that the glyceryl glycerol monostearate of the emulsifier (A) was changed to glyceryl succinate monostearate (Sunsoft No. 681NU, Taiyo Kagaku Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 4.3 mPa · s.
(Example 8)
In Example 6, the exact same preparation method as in Example 6 was repeated except that the glyceryl monostearate of emulsifier (A) was changed to glyceryl monostearate diacetyl tartrate (Poem W-10, Riken Vitamin Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 5.0 mPa · s.
Example 9
In Example 7, a whey protein nutritional composition was obtained by repeating exactly the same preparation method as in Example 6 except that 10 g / 10 L of decaglycerin monooleate as the emulsifier (B) was changed to 20 g / 10 L. The viscosity of the obtained whey protein nutrition composition was 4.3 mPa · s.
(Example 10)
In Example 7, a whey protein nutritional composition was obtained by repeating exactly the same preparation method as in Example 6 except that 10 g / 10 L of decaglycerin monooleate as the emulsifier (B) was changed to 30 g / 10 L. The viscosity of the obtained whey protein nutrition composition was 4.3 mPa · s.
(Example 11)
A whey protein nutrition composition was obtained by repeating exactly the same preparation method as in Example 6, except that 10 g / 10 L of decaglycerin monooleate as the emulsifier (B) was changed to 40 g / 10 L in Example 7. The viscosity of the obtained whey protein nutrition composition was 4.3 mPa · s.
(比較例7)
実施例7において、乳化剤(B)のデカグリセリンモノオレエートをデカグリセリンモノラウレート(SYグリスターML−750、阪本薬品工業株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は3.8mPa・sであった。
(比較例8)
実施例7において、乳化剤(B)のデカグリセリンモノオレエートをデカグリセリンモノステアレート(サンソフトQ−18S、太陽化学株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.8mPa・sであった。
(比較例9)
実施例7において、乳化剤(B)のデカグリセリンモノオレエートをデカグリセリンジステアレート(サンソフトQ−182S、太陽化学株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は5.4mPa・sであった。
(比較例10)
実施例7において、乳化剤(B)のデカグリセリンモノオレエートをヘキサグリセリンモノラウレート(SYグリスターML−500、阪本薬品工業株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は3.9mPa・sであった。
(比較例11)
実施例7において、乳化剤(B)のデカグリセリンモノオレエートをヘキサグリセリンモノオレエート(SYグリスターMO−5S、阪本薬品工業株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は3.9mPa・sであった。
(比較例12)
実施例7において、乳化剤(B)のデカグリセリンモノオレエートをテトラグリセリンモノオレエート(SYグリスターMO−3S、阪本薬品工業株式会社)に変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.0mPa・sであった。
(Comparative Example 7)
In Example 7, the same preparation method as in Example 6 was repeated except that the decaglycerin monooleate of emulsifier (B) was changed to decaglycerin monolaurate (SY Glyster ML-750, Sakamoto Yakuhin Kogyo Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 3.8 mPa · s.
(Comparative Example 8)
In Example 7, the same preparation method as in Example 6 was repeated except that decaglycerin monooleate of emulsifier (B) was changed to decaglycerin monostearate (Sunsoft Q-18S, Taiyo Kagaku Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 4.8 mPa · s.
(Comparative Example 9)
In Example 7, the same preparation method as in Example 6 was repeated except that decaglycerin monooleate of emulsifier (B) was changed to decaglycerin distearate (Sunsoft Q-182S, Taiyo Kagaku Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 5.4 mPa · s.
(Comparative Example 10)
In Example 7, the same preparation method as in Example 6 was repeated except that decaglycerin monooleate of emulsifier (B) was changed to hexaglycerin monolaurate (SY Glyster ML-500, Sakamoto Yakuhin Kogyo Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 3.9 mPa · s.
(Comparative Example 11)
In Example 7, the same preparation method as in Example 6 was repeated except that the decaglycerin monooleate of the emulsifier (B) was changed to hexaglycerin monooleate (SY Glyster MO-5S, Sakamoto Pharmaceutical Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 3.9 mPa · s.
(Comparative Example 12)
In Example 7, the same preparation method as in Example 6 was repeated except that the decaglycerin monooleate of the emulsifier (B) was changed to tetraglycerin monooleate (SY Glyster MO-3S, Sakamoto Yakuhin Kogyo Co., Ltd.). A whey protein nutritional composition was obtained. The viscosity of the obtained whey protein nutrition composition was 4.0 mPa · s.
(実施例13)
実施例7において、乳化剤(B)のデカグリセリンモノオレエート10g/10Lを5g/10Lに変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.2mPa・sであった。
(実施例14)
実施例7において、乳化剤(B)のデカグリセリンモノオレエート10g/10Lを50g/10Lに変えた以外は、実施例6と全く同じ調製法を繰り返して乳清たんぱく栄養組成物を得た。得られた乳清たんぱく栄養組成物の粘度は4.3mPa・sであった。
(Example 13)
In Example 7, a whey protein nutritional composition was obtained by repeating exactly the same preparation method as in Example 6 except that 10 g / 10 L of decaglycerin monooleate as the emulsifier (B) was changed to 5 g / 10 L. The viscosity of the obtained whey protein nutritional composition was 4.2 mPa · s.
(Example 14)
In Example 7, a whey protein nutritional composition was obtained by repeating exactly the same preparation method as in Example 6 except that 10 g / 10 L of decaglycerin monooleate as the emulsifier (B) was changed to 50 g / 10 L. The viscosity of the obtained whey protein nutrition composition was 4.3 mPa · s.
(評価法2)
実施例6から11と比較例7から14の乳清たんぱく栄養組成物の調製直後および60℃に7日間保存した後の状態を観察し、回折型粒度分布計SALD−300Vで平均粒径を測定した。結果を表5に示す。実施例1から3の乳化剤(B)の種類を変えた実施例6から8の乳清たんぱく栄養組成物の調製直後および60℃に7日間保存した後の状態は、いずれも均一な液状であり、平均粒径は、いずれも0.4μm以下であった。一方、実施例7の乳化剤(B)の種類を変えた比較例7から12の乳清たんぱく栄養組成物の調製直後の状態は、いずれも均一な液状であったが、60℃に7日間保存した後の状態は、クリーミングまたは凝集物を発生し、平均粒径は0.4μmより大きくなった。また、実施例7の乳化剤(B)の配合量を変えた実施例9から11の乳清たんぱく栄養組成物の調製直後および60℃に7日間保存した後の状態は、いずれも均一な液状であり、平均粒径は、いずれも0.4μm以下であった。一方、実施例7の乳化剤(B)の配合量を変えた比較例13および14の乳清たんぱく栄養組成物の調製直後の状態は、いずれも均一な液状であったが、60℃に7日間保存した後の状態は、クリーミングを発生し、平均粒径は0.4μmより大きくなった。
(Evaluation method 2)
Immediately after the preparation of the whey protein nutritional compositions of Examples 6 to 11 and Comparative Examples 7 to 14 and after storage at 60 ° C. for 7 days, the average particle size was measured with a diffraction type particle size distribution analyzer SALD-300V. did. The results are shown in Table 5. The state immediately after the preparation of the whey protein nutritional composition of Examples 6 to 8 in which the type of the emulsifier (B) of Examples 1 to 3 was changed and after storage at 60 ° C. for 7 days are all in a uniform liquid state. The average particle diameter was 0.4 μm or less. On the other hand, the conditions immediately after the preparation of the whey protein nutritional compositions of Comparative Examples 7 to 12 in which the type of the emulsifier (B) of Example 7 was changed were all uniform liquids, but stored at 60 ° C. for 7 days. After the treatment, creaming or agglomeration occurred, and the average particle size became larger than 0.4 μm. Moreover, the state immediately after preparation of the whey protein nutrition composition of Examples 9 to 11 in which the blending amount of the emulsifier (B) of Example 7 was changed and after being stored at 60 ° C. for 7 days are all in a uniform liquid state. The average particle size was 0.4 μm or less. On the other hand, the state immediately after the preparation of the whey protein nutritional compositions of Comparative Examples 13 and 14 in which the blending amount of the emulsifier (B) of Example 7 was changed was a uniform liquid, but at 60 ° C. for 7 days. The state after storage caused creaming and the average particle size was larger than 0.4 μm.
本発明は、乳清たんぱくを配合しても特定の乳化剤を組み合わせて乳化を行うことにより、製造工程中の均質化処理や加熱殺菌処理に耐え、調製後も乳化安定性が確保され、内容成分が均質で風味が良好であり、栄養補給を必要とする高齢者や患者等への栄養補給の際に摂取できるようにした乳清たんぱく栄養組成物であり、産業上、十分に利用できるものである。 The present invention can withstand homogenization and heat sterilization during the manufacturing process by emulsifying by combining a specific emulsifier even when whey protein is blended. Is a whey protein nutritional composition that is homogeneous and has a good flavor and can be taken in nutritional supplementation for the elderly and patients who need nutritional supplementation. is there.
Claims (5)
乳化剤として以下の(A)および(B)を含有し、(A)1重量部に対して乳化剤(B)を0.5〜3重量部配合し、加熱殺菌後に液状である乳清たんぱく栄養組成物。
(A)コハク酸グリセリンモノステアレート、乳酸グリセリンモノステアレート、ジアセチル酒石酸グリセリンモノステアレート、からなる群から選ばれる1以上の有機酸モノグリセリド、
(B)HLB値が12〜14、および、乳化剤を構成する脂肪酸の融点が60℃以下であるポリグリセリン脂肪酸エステル。 In a nutritional composition containing whey protein, lipids, carbohydrates, vitamins, minerals,
Whey protein nutritional composition containing the following (A) and (B) as an emulsifier, blending 0.5 to 3 parts by weight of the emulsifier (B) with respect to 1 part by weight of (A), and being liquid after heat sterilization object.
(A) one or more organic acid monoglycerides selected from the group consisting of glyceryl monostearate succinate, glyceryl monostearate lactate, glyceryl monostearate diacetyl tartrate,
(B) Polyglycerin fatty acid ester having an HLB value of 12 to 14 and a melting point of the fatty acid constituting the emulsifier of 60 ° C. or lower.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007255645A JP5189817B2 (en) | 2007-09-28 | 2007-09-28 | Whey protein nutritional composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007255645A JP5189817B2 (en) | 2007-09-28 | 2007-09-28 | Whey protein nutritional composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009084204A true JP2009084204A (en) | 2009-04-23 |
JP5189817B2 JP5189817B2 (en) | 2013-04-24 |
Family
ID=40658090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007255645A Active JP5189817B2 (en) | 2007-09-28 | 2007-09-28 | Whey protein nutritional composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5189817B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014208613A1 (en) * | 2013-06-26 | 2014-12-31 | 三菱化学フーズ株式会社 | Powder composition, method for producing same, and beverage |
WO2018179953A1 (en) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | High-calorie nutritional composition, and package |
WO2023190295A1 (en) * | 2022-03-31 | 2023-10-05 | ニュートリー株式会社 | Liquid nutritional composition and package |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09157179A (en) * | 1995-12-04 | 1997-06-17 | Terumo Corp | Liquid nourishing composition |
JPH09266778A (en) * | 1996-03-29 | 1997-10-14 | Kao Corp | High viscosity food dry matter |
JP2007110927A (en) * | 2005-10-18 | 2007-05-10 | Honen Lever Co Ltd | Foaming shortening |
-
2007
- 2007-09-28 JP JP2007255645A patent/JP5189817B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09157179A (en) * | 1995-12-04 | 1997-06-17 | Terumo Corp | Liquid nourishing composition |
JPH09266778A (en) * | 1996-03-29 | 1997-10-14 | Kao Corp | High viscosity food dry matter |
JP2007110927A (en) * | 2005-10-18 | 2007-05-10 | Honen Lever Co Ltd | Foaming shortening |
Non-Patent Citations (2)
Title |
---|
JPN6012036002; 戸田義郎, 他.: '2-2 モノグリセリド誘導体' 食品用乳化剤 -基礎と応用- , 19970401, p.26-34, 株式会社光琳 * |
JPN6012036004; 'グリセリン脂肪酸エステル' 医薬品添加物事典 , 20070725, p.83, 株式会社薬事日報社 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014208613A1 (en) * | 2013-06-26 | 2014-12-31 | 三菱化学フーズ株式会社 | Powder composition, method for producing same, and beverage |
JPWO2014208613A1 (en) * | 2013-06-26 | 2017-02-23 | 三菱化学フーズ株式会社 | Powder composition, method for producing the powder composition, and beverage |
WO2018179953A1 (en) * | 2017-03-30 | 2018-10-04 | テルモ株式会社 | High-calorie nutritional composition, and package |
JPWO2018179953A1 (en) * | 2017-03-30 | 2020-02-06 | テルモ株式会社 | High calorie nutrition composition and package |
JP7116044B2 (en) | 2017-03-30 | 2022-08-09 | テルモ株式会社 | High calorie nutritional composition and package |
WO2023190295A1 (en) * | 2022-03-31 | 2023-10-05 | ニュートリー株式会社 | Liquid nutritional composition and package |
JP7524490B2 (en) | 2022-03-31 | 2024-07-29 | ニュートリー株式会社 | Liquid nutritional composition and packaging |
CN118678890A (en) * | 2022-03-31 | 2024-09-20 | 营养株式会社 | Liquid nutritional composition and package |
Also Published As
Publication number | Publication date |
---|---|
JP5189817B2 (en) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10092625B2 (en) | Liquid enteral nutritional composition with a low monovalent metal ion content | |
DK2249666T3 (en) | Protein-rich liquid enteral nutritional composition on a casein basis | |
JP5963676B2 (en) | Enteral nutrition | |
US20110021421A1 (en) | Liquid enteral nutritional composition with a low specific protein volume | |
JP6242825B2 (en) | High energy liquid nutritional composition with improved sensory properties | |
JP5261114B2 (en) | Acid type liquid enteral nutrient | |
JP5384333B2 (en) | Liquid nutritional composition containing whey protein at high concentration and method for producing the same | |
JP2007126379A (en) | Method for producing acidic liquid enteral nutritive preparation | |
EP2938211B1 (en) | Method for the preparation of a liquid enteral nutritional composition comprising micellar casein | |
JP5189817B2 (en) | Whey protein nutritional composition | |
JP6586414B2 (en) | Nutritional composition | |
JP6753255B2 (en) | Liquid nutritional composition | |
KR102802329B1 (en) | Liquid nutritional composition and packaging | |
JP2021103991A (en) | Liquid nutritive composition | |
WO2017146141A1 (en) | Rehydration agent | |
RU2471370C2 (en) | Liquid enteral nutritional composition with low specific volume of protein | |
JP2005058018A (en) | Phospholipid-containing composition | |
CN119894379A (en) | Method for preparing enteral nutritional composition | |
JP2020156362A (en) | Liquid nutritive composition | |
HK1202381B (en) | Method for producing nutritional composition | |
HK1202381A1 (en) | Method for producing nutritional composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120831 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121009 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130125 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160201 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5189817 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |